We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| bluebird bio Inc | NASDAQ:BLUE | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.0274 | 3.00% | 0.9399 | 0.9237 | 0.9399 | 0.9458 | 0.893 | 0.9102 | 5,160,818 | 00:40:57 |
From Apr 2019 to Apr 2024
By Stephen Nakrosis
Bristol-Myers Squibb Co. (BMY) and bluebird bio Inc. (BLUE) said results from a Phase 2 study of their idecabtagene vicleucel treatment for certain myeloma patients met its primary endpoint and key secondary endpoint.
Idecabtagene vicleucel, or ide-cel, is an investigational treatment for certain patients with relapsed and refractory multiple myeloma, the companies said.
The KarMMa Phase 2 study "met its primary endpoint and key secondary endpoint, demonstrating deep and durable responses in a heavily pre-treated multiple myeloma patient population," the companies said.
The companies said they are "are actively preparing for submission of these data to health authorities for proposed initial registration of ide-cel as a first-in-class BCMA-targeted CAR T cell therapy."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 06, 2019 17:15 ET (22:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year bluebird bio Chart |
1 Month bluebird bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
